Loading clinical trials...

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients With Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse

NCT01281514•Fox Chase Cancer Center

View on ClinicalTrials.gov

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboplatin and PLD together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with carboplatin and PLD in treating patients with relapsed ovarian epithelial, fallopian tube, or peritoneal cavity cancer

Detailed Description

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of RAD001 (everolimus) in combination with carboplatin and PLD. SECONDARY OBJECTIVES: I. Determine safety/tolerability of the three drug combination of carboplatin, PLD and RAD001 (everolimus). II. Determine preliminary analysis of anti-tumor activity of this regimen in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers. OUTLINE: This is a dose-escalation study of everolimus. Patients receive carboplatin intravenously (IV) and PLD IV on day 1 and everolimus orally (PO) once daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months for 1 year.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
•Patients must have had exactly one prior platinum/taxane-based chemotherapeutic regimen for management of primary disease, and must be in first relapse; first relapse must occur \>= six months from completion of front-line platinum-based therapy; (time measured from last platinum dose; for example, patients receiving a biologic or chemotherapeutic agent after completion of platinum-based therapy as part of upfront therapy would be eligible based on time from last dose of platinum chemotherapy; in this situation, patients must be at least four weeks from last dose of a biologic agent); relapse cannot be based on rising cancer antigen (CA)- 125 alone; there must be radiographic evidence of recurrent disease
•Measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria or non-measurable disease with symptomatic malignant pleural effusion or malignant ascites; if only site of disease is a pleural effusion, cytologic confirmation of recurrence should be obtained
•Patients must not have any major surgery or radiation therapy within 14 days of start of study treatment
•All acute toxicities from prior therapy with the exception of alopecia must have resolved to =\< grade 1
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
•Absolute neutrophil count (ANC) \>= 1500
•Platelets \>= 100K
•Serum total bilirubin =\< 1.5x upper limit of normal (ULN)
•Serum transaminase (aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\], alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\]) activity =\< 2.5 x ULN
+8 more criteria

Exclusion Criteria

•Patients with more than one prior chemotherapy regimen for management of primary disease
•Patients who have received a prior mammalian target of rapamycin (mTOR) inhibitor
•Chronic treatment with systemic steroids or other immunosuppressive agents; Note: topical or inhaled steroids are allowed
•Uncontrolled brain or leptomeningeal metastases, including those who continue to require glucocorticoids for brain or leptomeningeal metastases
•Other malignancies =\< 3 years prior to registration except for adequately treated carcinoma of the cervix or basal or squamous carcinomas of the skin
•Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study; examples include, but are not limited to: uncontrolled diabetes defined as fasting serum glucose \> 1.5 x ULN; uncontrolled hypertension, or greater than 150/100 in spite of antihypertensive therapy; active (acute or chronic) or uncontrolled severe infection; unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association Class III or IV); ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months; liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
•Known history of human immunodeficiency virus (HIV) seropositivity as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agent
•Known history of Hepatitis B or C as these patients may be at risk of disease reactivation when treated with the chemotherapy and/or the investigational agent
•Patients should not receive immunization with attenuated live vaccines =\< 7 days of study entry or during study period
•Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection sufficient to impair absorption of drug)
+7 more criteria

Locations (1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

December 14, 2010

Primary Completion Date

January 8, 2018

Completion Date

January 8, 2018

Last Updated

July 11, 2019

Enrollment

ACTUAL participants

Conditions

Fallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer

Interventions

everolimus

DRUG

carboplatin

DRUG

pegylated liposomal doxorubicin hydrochloride

DRUG

laboratory biomarker analysis

OTHER

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian Cancer+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 11, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Study of AVZO-021 in Patients With Advanced Solid Tumors